ArticleeNeurologicalSci2026
Prognostic value of serial IL-6 and NSE measurements in acute ischemic stroke patients undergoing mechanical thrombectomy.
Article in eNeurologicalSci, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite major advances in acute stroke therapy, particularly mechanical thrombectomy (MT) for large-vessel occlusion, predicting outcomes in acute ischemic stroke (AIS) remains challenging. Secondary injury mechanisms such as neuroinflammation and neuronal damage contribute substantially to poor recovery, yet are insufficiently captured by clinical and imaging models alone. Interleukin-6 (IL-6) and neuron-specific enolase (NSE) represent complementary biomarkers of these processes, but their combined and serial prognostic value in MT-treated patients has not been fully defined. Aim: To evaluate the prognostic significance of serial plasma IL-6 and NSE measurements for predicting stroke severity, complications, and functional recovery in AIS patients undergoing MT. Methods: In this prospective study, 70 patients with AIS due to large-vessel occlusion treated with MT were enrolled. IL-6 and NSE were measured on Day1 and Days7-10. Associations with neurological severity (NIHSS), hemorrhagic transformation, and functional outcome (mRS) were analyzed. Multivariate linear regression and hierarchical logistic regression models were used to assess the incremental prognostic value of biomarkers beyond established clinical predictors. Results: Higher IL-6 and NSE levels were associated with greater neurological severity, unfavorable functional outcomes, and hemorrhagic transformation at both time points. NSE showed moderate correlations with NIHSS and mRS (R Conclusion: Serial assessment of IL-6 and NSE offers clinically meaningful insight into inflammatory and neurodestructive mechanisms that influence recovery after AIS treated with MT. In particular, dynamic IL-6 measurements provide measurable incremental prognostic value beyond baseline neurological severity, supporting their integration into multimodal risk-stratification strategies for personalized post-stroke management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.